...
首页> 外文期刊>Plastic and reconstructive surgery >A Randomized Controlled Trial of Skin Care Protocols for Facial Resurfacing: Lessons Learned from the Plastic Surgery Educational Foundation's Skin Products Assessment Research Study.
【24h】

A Randomized Controlled Trial of Skin Care Protocols for Facial Resurfacing: Lessons Learned from the Plastic Surgery Educational Foundation's Skin Products Assessment Research Study.

机译:适用于面部勘探的皮肤护理方案的随机对照试验:从整形外科教育基础的皮肤产品评估研究中汲取的经验教训。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: : The Skin Products Assessment Research Committee was created by the Plastic Surgery Educational Foundation in 2006. The Skin Products Assessment Research study aims were to (1) develop an infrastructure for Plastic Surgery Educational Foundation-conducted, industry-sponsored research in facial aesthetic surgery and (2) test the research process by comparing outcomes of the Obagi Nu-Derm System versus conventional therapy as treatment adjuncts for facial resurfacing procedures. METHODS: : The Skin Products Assessment Research study was designed as a multicenter, double-blind, randomized, controlled trial. The study was conducted in women with Fitzpatrick type I to IV skin, moderate to severe facial photodamage, and periocular and/or perioral fine wrinkles. Patients underwent chemical peel or laser facial resurfacing and were randomized to the Obagi Nu-Derm System or a standard care regimen. The study endpoints were time to reepithelialization, erythema, and pigmentation changes. RESULTS: : Fifty-six women were enrolled and 82 percent were followed beyond reepithelialization. There were no significant differences in mean time to reepithelialization between Obagi Nu-Derm System and control groups. The Obagi Nu-Derm System group had a significantly higher median erythema score on the day of surgery (after 4 weeks of product use) that did not persist after surgery. Test-retest photographic evaluations demonstrated that both interrater and intrarater reliability were adequate for primary study outcomes. CONCLUSIONS: : The authors demonstrated no significant difference in time to reepithelialization between patients who used the Obagi Nu-Derm System or a standard care regimen as an adjunct to facial resurfacing procedures. The Skin Products Assessment Research team has also provided a discussion of future challenges for Plastic Surgery Educational Foundation-sponsored clinical research for readers of this article.
机译:背景:皮肤产品评估研究委员会是由整形手术教育基金会创建的2006年。皮肤产品评估研究旨在(1)为面部审美制定整形外科教育基础,行业赞助研究的基础设施。手术和(2)通过将Obagi Nu-Derm系统与常规治疗的结果进行比较来测试研究过程作为面部重新铺设程序的治疗辅助程序。方法::皮肤产品评估研究研究设计为多中心,双盲,随机,对照试验。该研究是在孕妇的妇女中进行I型至IV皮肤,中度至严重的面部光电淋,和周边和/或完全细皱纹。患者接受了化学剥离或激光面部重压架,并随机随机化为Obagi Nu-Derm系统或标准护理方案。研究终点是对再次精英化,红斑和色素沉着的变化的时间。结果:参加五十六名女性,82%的含量超出了再次安全性。在Obagi Nu-Derm系统和对照组之间的同时性的平均差异没有显着差异。 Obagi Nu-Derm系统组在手术后的手术日(产品使用4周后)具有明显更高的红斑分数,在手术后不存在。测试重新测试的摄影评估表明,Interrater和Intrarberter可靠性都足以进行初级研究结果。结论:作者展示了将使用Obagi Nu-Derm系统或标准护理方案作为面部重新铺设程序的辅助程序的患者对患者的重新安全性的显着差异。皮肤产品评估研究团队还讨论了对本文读者的整形外科教育基础赞助临床研究的未来挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号